Notice of Interest Rate on Overdue Debts, 67364 [2013-26994]

Download as PDF 67364 Federal Register / Vol. 78, No. 218 / Tuesday, November 12, 2013 / Notices (2) that any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSsupported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract, and that the text in such submission is his own or properly cites the source of copied language and ideas; and (3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. [FR Doc. 2013–26991 Filed 11–8–13; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary emcdonald on DSK67QTVN1PROD with NOTICES Notice of Interest Rate on Overdue Debts Section 30.18 of the Department of Health and Human Services’ claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest, which is determined and fixed by the Secretary of the Treasury after considering private consumer rates of interest on the date that the Department of Health and Human Services becomes entitled to recovery. The rate cannot be lower than the Department of Treasury’s current value of funds rate or the applicable rate determined from the ‘‘Schedule of Certified Interest Rates with Range of Maturities’’ unless the Secretary waives interest in whole or part, or a different rate is prescribed by statute, contract, or repayment agreement. The Secretary of the Treasury may revise this rate quarterly. The Department of Health and Human Services publishes this rate in the Federal Register. The current rate of 10–1/8%, as fixed by the Secretary of the Treasury, is certified for the quarter ended September 30, 2013. This rate is based on the Interest Rates for Specific Legislation, ‘‘National Health Services 17:41 Nov 08, 2013 Jkt 232001 Dated: October 18, 2013. David C. Horn, Director, Office of Financial Policy and Reporting. [FR Doc. 2013–26994 Filed 11–8–13; 8:45 am] BILLING CODE 4150–04–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0001] Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: David E. Wright, Director, Office of Research Integrity. VerDate Mar<15>2010 Corps Scholarship Program (42 U.S.C. 254o(b)) and ‘‘National Research Service Award Program (42 U.S.C. 288(c)(4)(B)).’’ This interest rate will be applied to overdue debt until the Department of Health and Human Services publishes a revision. Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee. General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues. Date and Time: The meeting will be held on December 12, 2013, from 8 a.m. to 5 p.m. Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993– 0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/ AdvisoryCommittees/default.htm; under the heading ‘‘Resources for You,’’ click on ‘‘Public Meetings at the FDA White Oak Campus.’’ Please note that visitors to the White Oak Campus must enter through Building 1. Contact Person: Karen AbrahamBurrell, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301–796–9001, FAX: 301–847–8533, email: EMDAC@ fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http:// www.fda.gov/AdvisoryCommittees/ default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting. Agenda: The committee will discuss the efficacy and safety of new drug application (NDA) 202293, dapagliflozin tablet, submitted by Bristol-Myers Squibb. Dapagliflozin is a sodiumglucose cotransporter 2 inhibitor developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at: http://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee meeting link. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 27, 2013. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 19, 2013. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 20, 2013. Persons attending FDA’s advisory committee meetings are advised that the E:\FR\FM\12NON1.SGM 12NON1

Agencies

[Federal Register Volume 78, Number 218 (Tuesday, November 12, 2013)]
[Notices]
[Page 67364]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-26994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Notice of Interest Rate on Overdue Debts

    Section 30.18 of the Department of Health and Human Services' 
claims collection regulations (45 CFR part 30) provides that the 
Secretary shall charge an annual rate of interest, which is determined 
and fixed by the Secretary of the Treasury after considering private 
consumer rates of interest on the date that the Department of Health 
and Human Services becomes entitled to recovery. The rate cannot be 
lower than the Department of Treasury's current value of funds rate or 
the applicable rate determined from the ``Schedule of Certified 
Interest Rates with Range of Maturities'' unless the Secretary waives 
interest in whole or part, or a different rate is prescribed by 
statute, contract, or repayment agreement. The Secretary of the 
Treasury may revise this rate quarterly. The Department of Health and 
Human Services publishes this rate in the Federal Register.
    The current rate of 10-1/8%, as fixed by the Secretary of the 
Treasury, is certified for the quarter ended September 30, 2013. This 
rate is based on the Interest Rates for Specific Legislation, 
``National Health Services Corps Scholarship Program (42 U.S.C. 
254o(b)) and ``National Research Service Award Program (42 U.S.C. 
288(c)(4)(B)).'' This interest rate will be applied to overdue debt 
until the Department of Health and Human Services publishes a revision.

    Dated: October 18, 2013.
David C. Horn,
Director, Office of Financial Policy and Reporting.
[FR Doc. 2013-26994 Filed 11-8-13; 8:45 am]
BILLING CODE 4150-04-P